Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) is -10.44% lower on its value in year-to-date trading and has touched a low of $29.91 and a high of $67.66 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AMPH stock was last observed hovering at around $53.88 in the last trading session, with the day’s gains setting it 1.51%.
Currently trading at $55.39, the stock is -3.64% and -4.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.16 million and changing 2.80% at the moment leaves the stock 7.71% off its SMA200. AMPH registered 77.99% gain for a year compared to 6-month gain of -8.94%. The firm has a 50-day simple moving average (SMA 50) of $5.04 and a 200-day simple moving average (SMA200) of $13.44.
The stock witnessed a -11.98% loss in the last 1 month and extending the period to 3 months gives it a 23.25%, and is -0.95% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.16% over the week and 4.11% over the month.
Amphastar Pharmaceuticals Inc (AMPH) has around 1615 employees, a market worth around $2.65B and $601.31M in sales. Current P/E ratio is 21.62 and Fwd P/E is 14.95. Profit margin for the company is 22.50%. Distance from 52-week low is 85.19% and -18.13% from its 52-week high. The company has generated returns on investments over the last 12 months (10.71%).
Amphastar Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at $0.91 with sales reaching $176.6M over the same period.The EPS is expected to grow by 70.34% this year, but quarterly earnings will post 28.40% year-over-year. Quarterly sales are estimated to grow 30.80% in year-over-year returns.
Amphastar Pharmaceuticals Inc (AMPH) Top Institutional Holders
363 institutions hold shares in Amphastar Pharmaceuticals Inc (AMPH), with institutional investors hold 87.73% of the company’s shares. The shares outstanding are 48.11M, and float is at 36.01M with Short Float at 8.18%. Institutions hold 68.90% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 6.09 million shares valued at $349.89 million. The investor’s holdings represent 12.61% of the AMPH Shares outstanding. As of Jun 29, 2023, the second largest holder is Federated Hermes, Inc. with 3.43 million shares valued at $197.06 million to account for 7.10% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 2.77 million shares representing 5.75% and valued at over $159.4 million, while Dimensional Fund Advisors LP holds 4.00% of the shares totaling 1.93 million with a market value of $110.95 million.
Amphastar Pharmaceuticals Inc (AMPH) Insider Activity
A total of 23 insider transactions have happened at Amphastar Pharmaceuticals Inc (AMPH) in the last six months, with sales accounting for 15 and purchases happening 8 times. The most recent transaction is an insider sale by Luo Mary Z.,the company’sCOO,Chief Scientist & Chairman. SEC filings show that Luo Mary Z. sold 131,386 shares of the company’s common stock on Jan 10 at a price of $54.59 per share for a total of $7.17 million. Following the sale, the insider now owns 1.1 million shares.
Amphastar Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 09 that Luo Mary Z. (COO,Chief Scientist & Chairman) sold a total of 86,156 shares of the company’s common stock. The trade occurred on Jan 09 and was made at $57.14 per share for $4.92 million. Following the transaction, the insider now directly holds 1.24 million shares of the AMPH stock.
Still, SEC filings show that on Jan 08, Luo Mary Z. (COO,Chief Scientist & Chairman) disposed off 133,644 shares at an average price of $58.93 for $7.88 million. The insider now directly holds 1,321,958 shares of Amphastar Pharmaceuticals Inc (AMPH).
Amphastar Pharmaceuticals Inc (AMPH): Who are the competitors?
The company’s main competitors (and peers) include SCYNEXIS Inc. (SCYX) that is trading 6.27% up over the past 12 months. Agile Therapeutics Inc. (AGRX) that is -88.15% lower over the same period.